If you watch television, even just a little bit, you can’t help noticing the myriad ads for drugs that claim to treat (not cure) ailments ranging from mosquito bites to depression and congestive heart failure. There are so many drugs being advertised, more than the legal ads that offer help in suing some of the manufacturers of those drugs, that one might think it’s a simple affair for a company to push its pills onto the market. Of course, we tech savvy folk know that’s not the case.
The workflow of drug development is somewhat concise however.
Pinpoint the need. What condition do you want to treat (cure if you get lucky)?- Research what’s already being used and its effectiveness and determine if there is a need/market for an improved or unique drug.
- Decide to improve an existing drug or create a new one
- Research and experiment to discover the improvement or unique drug
- Appropriate and ethical testing of your improved or unique drug. If trials are successful, go to the next step. If not, well….the drawing board still has your name on it.
- Get appropriate agency approvals for your elixir. The big one is the Federal Drug Administration (FDA).
- If all goes well and you have your approvals, you can start advertising your drug, sell it, and hope to put some profits aside for a legal team for when your drug starts showing up in those legal ads.
Although clear, the workflow in drug development can get quite discombobulated with deadlines, various expected and unexpected setbacks, delays, accidents, and a plethora of other distractions and impedances. It would not be surprising to find that the bulk of over-the-counter headache medications are sold to medical researchers.
If this is your business, these troubles and tribulations may become a thing of the past, or minimized at the very least. Knowledge is power and you have the ability to acquire much of that power from Eyal Aklimi, Lead Electrical Engineer at Vium, Inc. He will be presenting a session titled “Sensors in Biotech: Revolutionizing Drug Discovery with High Quality Data” on Wednesday, October 17 from 9:10 AM to 10:00 AM at Sensors Midwest.
Eyal Aklimi has over 15 years of professional experience, most recently he is the Lead Electrical Engineer for Vium, Inc., a biotech company in San Mateo, CA. Prior to Vium, he was the Lead Electronics Innovator at Diamond Nanotechnologies, an R&D start-up in Boston, MA.
Eyal holds a Ph.D. in Electrical Engineering from Columbia University and B.Sc. in Electrical Engineering and Physics from Tel-Aviv University. Eyal has been published in several scientific journals that recognize his innovations in sensors, power electronics, and magnetism. Eyal is an avid contributor and has presented at various academic and industry conferences. Eyal was also a co-founder of Jux (currently YCD-Atmosphere), a multi-million-dollar media distribution algorithms company.
Eyal will discuss how state-of-the-art sensing platforms are leveraged to improve drug discovery workflow, which currently suffers from inconsistent, infrequent, and biased clinical data. Automated data acquisition from image, flow, light, and other sensors, provides unprecedented depth of insight into critical experimental aspects.
This session discusses a powerful platform, which improves accuracy and reduces variability of experiments. Optimal performance allows for smaller and faster experiments, ultimately offering better drug discovery.
Of course, all of this means nothing unless you register for Sensors Midwest 2018 in Rosemont, IL, October 16 to 17 and attend Dr. Aklimi’s session, “Sensors in Biotech: Revolutionizing Drug Discovery with High Quality Data.”
